(RTTNews) – Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) on Monday said the European Commission has approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years who have an inadequate response to histamine-1 a